TCL-089: Clinicopathological Presentation of Peripheral T-Cell Lymphoma and Their Prognostic Factors: A Single Center Experience

Abstract

<h3>Background</h3> Peripheral T-cell lymphomas (PTCLs) represent an uncommon and heterogeneous group of diseases. They comprise 10-15% of NHL, with epidemiological majority in South American and Asian populations. Historically these groups of malignancies have presented a poor prognosis, however, with the incorporation of brentuximab and autologous stem cell transplantation (ASCT) as consolidation strategy, the overall survival has improved. <h3>Objectives</h3> Describe the clinicopathological presentation of patients with PTLCs and review their prognosis features. <h3>Design</h3> Retrospective, observational study that included patients over 18 years with diagnosis of PTLCs, between January 2010 and December 2019. All of them were followed up at the HIBA. <h3>Results</h3> We included 43 patients with PTLCs diagnosis. The median age was 58 years (range 20-90) and 65% were male. The most common histopathological subtype was PTLC-NOS in 42% (n=18) followed by ALCL ALK- and AITL with 23% (n=10) and 14% (n=6) respectively. The 81% presented III/IV stage at the diagnosis and 58% had evidence of extranodal disease. Considering IPI and PIT scores, high risk populations slightly differ from 53% in the first score to 44% in the other. Nearly 80% of the patients received protocols including anthracyclines such as CHOEP in 44% (n=19) or CHOP in 32% (n=14) as first line treatment. Another 7% used brentuximab + CHP and 41% (n=18) of the total underwent ASCT as consolidation therapy. Almost 58% achieved complete remission. The overall survival (OS) at 5 years was 37% (IC 95% 20-56) with a median of 36 months. Variables significantly associated with OS were age range (48% vs 26% in under 60 years; p=0,12) and IPI score (65% <i>vs</i> 25% in low-risk groups; p=0.0044). Moreover, ASCT was associated with better OS and PFS with 61% and 58% respectively; <i>versus</i> 26% and 28% in the group without transplant (p=0,0064). <h3>Conclusions</h3> In our experience, PTLCs represent an ominous diagnosis with high mortality in older people and high-risk groups. ASCT showed improvement in OS. Nevertheless, the implementation of brentuximab is still being studied because of the few patients receiving this therapy at the moment.